.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Cipla
Baxter
Covington
Teva
US Army
QuintilesIMS
Boehringer Ingelheim
Harvard Business School

Generated: July 26, 2017

DrugPatentWatch Database Preview

Suppliers and packages for generic ingredient: INSULIN GLARGINE; LIXISENATIDE

« Back to Dashboard

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673NDASanofi-Aventis U.S. LLC0024-5761-055 SYRINGE in 1 CARTON (0024-5761-05) > 3 mL in 1 SYRINGE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Department of Justice
Argus Health
McKinsey
Teva
Chubb
Covington
Moodys
Citi
Dow

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot